Eye Imaging and Blood Markers for Early Detection of Alzheimer's Disease
Studies eye imaging and blood markers to detect Alzheimer's disease early in adults over 50.
Key facts
- Who runs it
- Peking University First Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 19 Mar 2025
- Expected to end
- 31 Aug 2027
- Type of study
- Observational
- Treatments tested
- Multimodal Ophthalmic Imaging and plasma biomarker
- Record updated
- 29 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 50 or older who have Alzheimer's disease, mild or subjective memory and thinking decline, or normal thinking. Eye imaging and blood tests will be used.
- Age
- 50 years or older
- Sex
- Men and women
- Disease stage
- Alzheimer's disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN)
Main reasons for not taking part
- Other brain or nerve disorders or body-wide diseases that may cause memory and thinking problems
- Cannot cooperate with memory and thinking tests
- Refuses to give a blood sample
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Male or female participants aged ≥ 50 years
- Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN)
- Signed informed consent form
Who cannot take part
- Presence of other neurological disorders and systemic diseases that may cause cognitive impairment
- Inability to cooperate with cognitive assessments
- Refusal to undergo blood sampling
Where in China
- Peking University First HospitalBeijing, ChinaContact: Yong an Prof.SunTaking people
About the trial
What the trial wants to find out
With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).
The group in the trial
- Different stages of Alzheimer's disease
Treatment: Multimodal Ophthalmic Imaging and plasma biomarker
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease
- Plain-language title
- Eye Imaging and Blood Markers for Early Detection of Alzheimer's DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 September 2026